Answers are grounded in this paper and cite their sources.
Exploring the potential of blood biomarkers and clinical indicators following traumatic brain injury (TBI) can offer valuable diagnostic and predictive insights.S100B, a well-studied blood biomarker in the context of TBI, has yielded inconclusive findings regarding its ability to distinguish TBI severity and predict outcomes.This study aims to verify the utility of S100B blood levels as predictive factors for TBI severity and patient outcomes.This study included 85 TBI patients (with Glasgow coma scale scores ranging from 3 to 15) admitted to the neurosurgery department.Blood serum samples were collected within 48 h of the traumatic incident and analyzed for S100B concentrations.Patient demographics, injury mechanisms, CT brain scan results, and Glasgow Coma scale scores were also recorded.Patient outcomes were evaluated using the Glasgow outcome scale extended, dichotomized into favourable vs. unfavourable and deceased vs. alive at three and six months post-injury.Upon admission, S100B serum levels significantly varied among mild, moderate, and severe TBI groups (p=0.000).Subsequent post hoc analysis confirmed a significant distinction in S100B concentration between mild vs. severe (p=0.000) and moderate vs. severe (p=0.004)TBI.S100B concentrations at admission effectively distinguished between favourable and unfavourable outcomes at three months of follow-up (p=0.000).Median serum levels were notably higher among deceased patients.The protein exhibited an inverse correlation with the initial Glasgow coma scale score and the Glasgow outcome scale extended outcome scores at three and six months, categorized as favourable (GOSE5-8) and unfavourable (GOSE1-4) outcomes.A positive correlation was observed with the total scores of Rotterdam CT brain categorization (p=0.289,p=0.005).S100B demonstrated moderate discriminative ability, with sensitivities of 72%, 71%, 72%, and 74% in predicting severity, mortality, and poor outcomes at three and six months, respectively.Incorporating on-admission S100B levels into the assessment of TBI may serve as an additional reliable tool for predicting patient outcomes and tailoring treatment strategies accordingly.
No takes yet. Share an insight, caveat, or question.
Mayur et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: